Molnupiravir as an Early Treatment for COVID-19: A Real Life Study

Objectives: Below we report our experience in the use of molnupiravir, the first antiviral drug against SARS-CoV-2 available to us, in the treatment of patients with COVID-19. Materials and Methods: We enrolled patients diagnosed with COVID-19 and comorbidities who were candidates for antiviral drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Pontolillo, Michela, Ucciferri, Claudio, Borrelli, Paola, Di Nicola, Marta, Vecchiet, Jacopo, Falasca, Katia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610792/
https://www.ncbi.nlm.nih.gov/pubmed/36297178
http://dx.doi.org/10.3390/pathogens11101121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610792/
https://www.ncbi.nlm.nih.gov/pubmed/36297178
http://dx.doi.org/10.3390/pathogens11101121

Ejemplares similares